Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Placebo-controlled Proof-of-Concept (PoC) Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Conditions
Interventions
efzofitimod 450 mg
efzofitimod 270 mg
+1 more
Locations
15
United States
aTyr Investigative Site
Los Angeles, California, United States
aTyr Investigative Site
San Diego, California, United States
aTyr Investigative Site
Miami, Florida, United States
aTyr Investigative Site
Chicago, Illinois, United States
aTyr Investigative Site
Chicago, Illinois, United States
aTyr Investigative Site
Chicago, Illinois, United States
Start Date
October 26, 2023
Primary Completion Date
April 1, 2026
Completion Date
April 1, 2026
Last Updated
May 7, 2025
NCT07484243
NCT06992661
NCT07077486
NCT05878717
NCT07300696
NCT06626438
Lead Sponsor
aTyr Pharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions